Ambit Biosciences
<b>Corporate Headquarters</b>
4215 Sorrento Valley Boulevard
San Diego
California
92121
United States
Tel: 858-334-2100
Fax: 858-334-2199
Website: http://www.ambitbio.com/
Email: info@ambitbio.com
94 articles about Ambit Biosciences
-
Ex-Ambit Biosciences CEO Takes Helm at HemaFLO Therapeutics
1/19/2016
-
Ambit Biosciences And Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society of Hematology
12/5/2014
-
Daiichi Sankyo, Inc. And Ambit Biosciences Announce Results Of Tender Offer
11/11/2014
-
Ambit Biosciences Announces Expiration Of Hart-Scott-Rodino Waiting Period
10/30/2014
-
Announcement Regarding Submission Of Tender Offer For Shares In Ambit Biosciences
10/15/2014
-
Daiichi Sankyo, Inc. Boosts Cancer Pipeline With $410 Million Ambit Biosciences Buy
9/29/2014
-
Ambit Biosciences Announces Participation At Baird 2014 Health Care Conference
8/27/2014
-
Ambit Biosciences Announces Second Quarter 2014 Operating Results
8/13/2014
-
Ambit Biosciences To Announce Second Quarter 2014 Financial Results
7/29/2014
-
Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 19th Congress Of The European Hematology Association
6/12/2014
-
Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 2014 Annual Meeting Of The American Society of Clinical Oncology
6/4/2014
-
Ambit Biosciences Announces Changes To Board Of Directors
6/4/2014
-
Ambit Biosciences Announces Participation At Jefferies and Co. 2014 Global Healthcare Conference
5/28/2014
-
Ambit Biosciences Announces First Quarter 2014 Operating Results
5/7/2014
-
Ambit Biosciences Announces Participation At Deutsche Bank 39th Annual Healthcare Conference
5/1/2014
-
Ambit Biosciences Announces Presentations Of Data From Clinical Investigations Of Quizartinib At The Annual Meeting Of The American Society of Clinical Oncology
4/23/2014
-
Ambit Biosciences To Announce First Quarter 2014 Financial Results
4/22/2014
-
Ambit Biosciences Initiation Of Quizartinib QUANTUM-R Phase 3 Trial
4/8/2014
-
Ambit Biosciences Announces Initiation Of Phase 2 Cohort In MD Anderson Cancer Center Sponsored Study Of Quizartinib In AML And High Risk MDS
4/7/2014
-
Ambit Biosciences Announces Fourth Quarter And Full-Year 2013 Operating Results
3/21/2014